Quantum and molecular modelling of abrocitinib as a potential disruptor of cell polarity in colorectal cancer
Open Access
- 12 November 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Abstract
Colorectal cancer (CRC) remains a major global health challenge, with chronic inflammation and disruption of epithelial polarity identified as key drivers of tumor progression. Polarity complexes such as Scribble–Mutated in Colorectal Cancer (MCC) are central to maintaining epithelial homeostasis, and their dysregulation has been linked to oncogenic transformation. Drug repurposing offers a promising strategy to accelerate therapeutic discovery by identifying new applications for clinically approved agents. In this study, we investigated abrocitinib (ABR), a selective JAK1 inhibitor, as a candidate for repurposing in CRC. Density functional theory (DFT) calculations at the PBE0-D3/6-31G(d) level were used to examine its electronic properties, including geometry optimization, natural bond orbital (NBO) analysis, molecular electrostatic potential (MESP) mapping, and Fukui function analysis. ABR exhibited a moderate HOMO–LUMO gap (1.827 eV) and an electrophilicity index of 3.492 eV, consistent with favorable reactivity and stability. Molecular docking with the Scribble PDZ1 domain (PDB ID: 6MTV) predicted a strong binding affinity (MolDock score − 78.66 kcal/mol; rerank score − 55.69 kcal/mol), supported by electrostatic and hydrophobic interactions. Importantly, comparative docking with fluorouracil and capecitabine demonstrated that ABR achieved more favorable binding energies and greater interaction stability than these reference CRC drugs, highlighting its superior potential to disrupt Scribble–MCC interactions. Monte Carlo simulations and normal mode analysis further confirmed the dynamic stability of the ABR–PDZ1 complex. Collectively, these findings provide preliminary evidence that abrocitinib may act as a promising modulator of polarity-regulating protein–protein interactions in CRC. While experimental validation remains necessary, this study establishes a computational framework that supports further biochemical and cellular investigations into abrocitinib’s potential as a repurposed therapeutic candidate.Keywords
This publication has 45 references indexed in Scilit:
- Driving forces and large scale affinity calculations for piperine/γ-cyclodxetrin complexes: Mechanistic insights from umbrella sampling simulation and DFT calculationsCarbohydrate Polymers, 2024
- Wnt/β-catenin signalling, epithelial-mesenchymal transition and crosslink signalling in colorectal cancer cellsBiomedicine & Pharmacotherapy, 2024
- The logic of protein post‐translational modifications (PTMs): Chemistry, mechanisms and evolution of protein regulation through covalent attachmentsBioEssays, 2024
- The role of the tumor microenvironment in colorectal cancer and the potential therapeutic approachesJournal of Clinical Laboratory Analysis, 2022
- A computer-aided drug design approach to discover tumour suppressor p53 protein activators for colorectal cancer therapyBioorganic & Medicinal Chemistry, 2022
- A New Approach to Design High Spin Organic Systems: Aromatic Stabilization with Exo‐cyclic π Electrons Plays Crucial RoleChemistrySelect, 2020
- Structural analysis and rational design of orthogonal stacking system in an E. coli DegP PDZ1–peptide complexChemical Papers, 2019
- System‐Dependent Dispersion Coefficients for the DFT‐D3 Treatment of Adsorption Processes on Ionic SurfacesChemphyschem, 2011
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- Directional Aspects of Intermolecular Interactions1998